Biotech »

Veritas Pharma increases lab staff for clinical trial

Veritas Pharma increases lab staff for clinical trial

Alpha Stox May 8, 2017 Comments Off

Dr. Lui Franciosi reports CANNEVERT PRESSES ON TO ITS GOAL OF CLINICAL TRIALS Veritas Pharma Inc.’s research arm, Cannevert Therapeutics Ltd. is moving swiftly toward properly certified and scientifically rigorous clinical trials of a

Read More »
SQI Diagnostics to provide Q2 results May 10

SQI Diagnostics to provide Q2 results May 10

Alpha Stox May 3, 2017 Comments Off

Toronto, Ontario, May 3, 2017 SQI Diagnostics Inc. (“SQI Diagnostics” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results for the three and six

Read More »
SQI Diagnostics to exhibit at biotechnology conference

SQI Diagnostics to exhibit at biotechnology conference

Alpha Stox May 1, 2017 Comments Off

Mr. Andrew Morris reports SQI DIAGNOSTICS TO EXHIBIT AT THE NATIONAL BIOTECHNOLOGY CONFERENCE SQI Diagnostics Inc. will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego, Calif.

Read More »
RepliCel Life receives U.S. patent for injection device

RepliCel Life receives U.S. patent for injection device

Alpha Stox April 25, 2017 Comments Off

Mr. Lee Buckler reports UNITED STATES PATENT ISSUED TO REPLICEL FOR ITS NOVEL DERMAL INJECTION TECHNOLOGIES RepliCel Life Sciences Inc. has been granted a key patent in the United States (U.S. patent No. 9,616,182)

Read More »
Bellus Health receives U.S. patent for BLU-5937

Bellus Health receives U.S. patent for BLU-5937

Alpha Stox April 24, 2017 Comments Off

Mr. Roberto Bellini reports BELLUS HEALTH ANNOUNCES GRANT OF NEW U.S. PATENT COVERING LEAD COMPOUND FOR CHRONIC COUGH The U.S. Patent and Trademark Office has issued U.S. patent No. 9,598,409, which grants claims covering

Read More »
ProMetic trial to exclude pirfenidone, PBI-4050 combo

ProMetic trial to exclude pirfenidone, PBI-4050 combo

Alpha Stox April 18, 2017 Comments Off

Mr. Pierre Laurin reports FDA CONFIRMS PROMETIC’S PBI-4050 IPF CLINICAL TRIAL DESIGN Prometic Life Sciences Inc. has received concurrence from the U.S. Food and Drug Administration (FDA) on the design of the first of

Read More »
Ventripoint Diagnostics Ltd is Featured on CEO Clips Airing on BNN

Ventripoint Diagnostics Ltd is Featured on CEO Clips Airing on BNN

Alpha Stox March 30, 2017 Comments Off

Toronto, Ontario – March 30, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) is please to announce the Corporation is being featured this week on CEO Clips airing on BNN.  CEO Clips,

Read More »
Ventripoint holders convert all outstanding debentures

Ventripoint holders convert all outstanding debentures

Alpha Stox March 29, 2017 Comments Off

Dr. George Adams reports VENTRIPOINT ANNOUNCES CONVERSION OF ALL OUTSTANDING DEBENTURES AND EXERCISE OF WARRANTS Ventripoint Diagnostics Ltd. is now debt-free, due to the conversion of all outstanding debentures previously issued by the corporation.

Read More »
SQI Diagnostics signs agreement to partner on revolutionary cardiac event prediction test

SQI Diagnostics signs agreement to partner on revolutionary cardiac event prediction test

Alpha Stox March 27, 2017 Comments Off

Toronto, Ontario, March 27, 2017SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”),

Read More »
Ventripoint closes $3.35-million placement

Ventripoint closes $3.35-million placement

Alpha Stox March 24, 2017 Comments Off

Dr. George Adams reports VENTRIPOINT ANNOUNCES CLOSING OF PRIVATE PLACEMENT Ventripoint Diagnostics Ltd. has closed its previously announced non-brokered private placement of 10,496,938 units at 32 cents per unit for total gross proceeds of

Read More »
Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1